hematologic neoplasms

Summary

Summary: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Top Publications

  1. ncbi Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
    Milena Sant
    Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Blood 116:3724-34. 2010
  2. ncbi Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8, Taihaku cho Hakata ku, Fukuoka, 812 0033, Japan
    Int J Infect Dis 15:e277-81. 2011
  3. ncbi Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50935 Cologne, Germany
    Clin Infect Dis 36:1103-10. 2003
  4. ncbi Flow cytometric immunophenotyping for hematologic neoplasms
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Blood 111:3941-67. 2008
  5. ncbi Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
  6. ncbi Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
    Scott C Kogan
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 100:238-45. 2002
  7. ncbi Fertility considerations and preservation in haemato-oncology patients undergoing treatment
    Avi Leader
    Department of Medicine A, Meir Medical Centre, Kfar Saba, Israel
    Br J Haematol 153:291-308. 2011
  8. pmc Late congestive heart failure after hematopoietic cell transplantation
    Saro H Armenian
    Division of Hematology Oncology, Childrens Hospital Los Angeles, USA
    J Clin Oncol 26:5537-43. 2008
  9. ncbi Does rituximab increase the incidence of infectious complications? A narrative review
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS 37 121, Los Angeles, CA 90095, USA
    Int J Infect Dis 15:e2-16. 2011
  10. pmc Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies
    Rodrigo Martino
    Department of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, and Autonomous University of Barcelona, Spain
    Biol Blood Marrow Transplant 11:781-96. 2005

Detail Information

Publications393 found, 100 shown here

  1. ncbi Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
    Milena Sant
    Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Blood 116:3724-34. 2010
    ..Differences in diagnostic and registration criteria are an important cause of incidence variation; however, different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement...
  2. ncbi Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8, Taihaku cho Hakata ku, Fukuoka, 812 0033, Japan
    Int J Infect Dis 15:e277-81. 2011
    ..This study assessed the effect of discontinuing quinolone prophylaxis on the etiology and the resistance pattern of blood culture isolates and on the prognosis among febrile neutropenic patients receiving chemotherapy...
  3. ncbi Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50935 Cologne, Germany
    Clin Infect Dis 36:1103-10. 2003
    ..The source of BSI was not determined for 57% of patients. The crude mortality rate was 36% for neutropenic patients and 31% for nonneutropenic patients...
  4. ncbi Flow cytometric immunophenotyping for hematologic neoplasms
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Blood 111:3941-67. 2008
    ..remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded ..
  5. ncbi Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
    ..Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell-dose barrier that limits the use of UCB in many adults and adolescents...
  6. ncbi Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
    Scott C Kogan
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 100:238-45. 2002
    ..This classification will be of particular value to investigators seeking to develop, use, and communicate about mouse models of human hematopoietic neoplasms...
  7. ncbi Fertility considerations and preservation in haemato-oncology patients undergoing treatment
    Avi Leader
    Department of Medicine A, Meir Medical Centre, Kfar Saba, Israel
    Br J Haematol 153:291-308. 2011
    ..Pre-pubertal patients present a unique constellation of fertility considerations, especially as embryo and sperm cryopreservation are not applicable to this age group...
  8. pmc Late congestive heart failure after hematopoietic cell transplantation
    Saro H Armenian
    Division of Hematology Oncology, Childrens Hospital Los Angeles, USA
    J Clin Oncol 26:5537-43. 2008
    ....
  9. ncbi Does rituximab increase the incidence of infectious complications? A narrative review
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS 37 121, Los Angeles, CA 90095, USA
    Int J Infect Dis 15:e2-16. 2011
    ..However, clinical experience regarding the association of rituximab with different types of infection is lacking and this association has not been established in patients with rheumatoid arthritis...
  10. pmc Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies
    Rodrigo Martino
    Department of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, and Autonomous University of Barcelona, Spain
    Biol Blood Marrow Transplant 11:781-96. 2005
    ..In addition, human metapneumovirus should be added to the potentially serious causes of RV infections in HSCT...
  11. ncbi Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study
    Agostino Cortelezzi
    Department of Haematology and Bone Marrow Transplantation Unit, IRCCS Fondazione Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
    Br J Haematol 129:811-7. 2005
    ..This study shows that the impact on clinical practice of symptomatic CVC-related thrombotic complications is not negligible in patients with haematological malignancies...
  12. ncbi Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy
    S Hashino
    Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita ku, Sapporo 060 8638, Japan
    Eur J Clin Microbiol Infect Dis 31:173-8. 2012
    ..We conclude that cycling the administration of antibiotics in patients with FN is useful for suppressing the appearance of multi-drug-resistant bacteria and for obtaining excellent clinical efficacy...
  13. ncbi The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit
    M Craig
    Department of Medicine, Mary Babb Randolph Cancer Center, West Virginia University Hospitals, Morgantown, WV 26506 9162, USA
    Bone Marrow Transplant 39:477-82. 2007
    ..gram-negative bacteremia was significantly decreased, without emergence of resistance. Concerns with Gram-positive resistance will require further observation...
  14. ncbi Nosocomial infections among pediatric hematology/oncology patients: results of a prospective incidence study
    Mireya Urrea
    Quality Service Infection Hospital Program, Hospital Sant Joan de Deu, Barcelona, Spain
    Am J Infect Control 32:205-8. 2004
    ..NI cause considerable morbidity and mortality and are associated with prolonged hospital stay and increased health care costs...
  15. doi Progress in the curative treatment of childhood hematologic malignancies
    Alan S Wayne
    J Natl Cancer Inst 100:1271-3. 2008
  16. ncbi Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications
    Margret S Rodrigues
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antioxid Redox Signal 10:1813-48. 2008
    ..The underlying mechanisms leading to elevated oxidative stress are reviewed, and signaling mechanisms that may serve as novel targeted approaches to overcome ROS-dependent cell growth are discussed...
  17. ncbi Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation
    Agostinho Carvalho
    Microbiology, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy
    Exp Hematol 37:1022-9. 2009
    ..Discovery of genetic variations in the genes encoding for Toll-like receptors (TLRs) has highlighted a potential link between genomic variation of the host and susceptibility to infections...
  18. ncbi Epidemiology of hematological malignancies
    D Rodriguez-Abreu
    IOSI, Oncology Institute of Southern Switzerland, Medical Oncology Department, Ospedale San Giovanni, Bellinzona, Switzerland
    Ann Oncol 18:i3-i8. 2007
  19. pmc Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
    Oliver A Cornely
    Klinikum der Universität zu Köln, Klinik I für Innere Medizin Zentrum für Klinische Studien BMBF 01KN0706, Koln, Germany
    Haematologica 94:113-22. 2009
    ..Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II)...
  20. ncbi Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
    D Caillot
    Department of Clinical Hematology, University Hospital of Dijon, Dijon, France
    J Clin Oncol 19:253-9. 2001
    ..In patients with neutropenia, thoracic computed tomography (CT) halo and air-crescent signs are recognized as major indicators of invasive pulmonary aspergillosis (IPA). Nevertheless, the exact timing of CT images is not well known...
  21. pmc Epigenetic inactivation of the miR-124-1 in haematological malignancies
    Kwan Yeung Wong
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
    PLoS ONE 6:e19027. 2011
    ..Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study...
  22. ncbi Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum UMK, Bydgoszcz, Poland
    Bone Marrow Transplant 43:757-70. 2009
    ..The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria...
  23. ncbi Epigenetic changes in solid and hematopoietic tumors
    Minoru Toyota
    Sapporo Medical University, Sapporo, Japan
    Semin Oncol 32:521-30. 2005
    ..Pharmacologic manipulation of these patterns-epigenetic therapy-is also poised to change the way we treat cancer in the clinic...
  24. ncbi Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors
    Silke Schelenz
    Department of Microbiology, Norfolk and Norwich University Hospital, Norwich, UK
    J Oral Pathol Med 40:83-9. 2011
    ..The aim of this study was to investigate the epidemiology of oral yeast colonization and infection amongst cancer patients...
  25. pmc Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis MN, USA
    Blood 110:3064-70. 2007
    ..01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients...
  26. pmc Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public
    M A Svec
    Department of Epidemiology, University of Washington, Seattle, Washington, USA
    Occup Environ Med 62:726-35. 2005
    ..Occupational exposure to animals or the public could result in exposure to infectious agents, which may play a role in the aetiology of lymphohaematopoietic (LH) cancers...
  27. pmc Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort
    Laura E Beane Freeman
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 101:751-61. 2009
    ....
  28. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  29. ncbi Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  30. ncbi Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates
    Ian Nivison-Smith
    ABMTRR, Darlinghurst NSW, Australia
    Biol Blood Marrow Transplant 15:1323-30. 2009
    ..Late deaths from transplant and disease-related causes are unusual, but continue to occur for many years post-HCT...
  31. pmc Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde
    Michael Hauptmann
    Department of Bioinformatics and Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Natl Cancer Inst 101:1696-708. 2009
    ..We investigated the relation of mortality to work practices and formaldehyde exposure levels among these professionals to address cancer risk in the funeral industry...
  32. ncbi The role of microRNAs in normal and malignant hematopoiesis
    Diamantina Vasilatou
    Second Department of Internal Medicine, University of Athens, University General Hospital Attikon, Haidari, Greece
    Eur J Haematol 84:1-16. 2010
    ..The purpose of this review is to summarize current knowledge on the role of microRNAs in normal hematopoiesis and hematopoietic malignancies and, moreover, to highlight their role as potential therapeutic tools...
  33. ncbi Acute interstitial pneumonitis during chemotherapy for haematological malignancy
    K Nakase
    The Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    Eur J Cancer Care (Engl) 14:336-41. 2005
    ..High dose steroid hormone should be used as therapy for such patients as soon as possible after exclusion of an infective aetiology...
  34. ncbi Molecular cytogenetic aspects of hematological malignancies: clinical implications
    Zhong Chen
    Cytogenetics Laboratory, Room 1C210 SOM, Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    Am J Med Genet 115:130-41. 2002
    ..With such information, the physician is in a more favorable position to devise therapy, appraise diagnosis, and plan follow-up...
  35. ncbi Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan
    Kensuke Ohta
    Department of Hematology, Saiseikai Nakatsu Hospital Osaka, Osaka, Japan
    Int J Hematol 89:649-55. 2009
    ..5% (8/13) and 100% (5/5), respectively. These results not only proved the good efficacy and safety of empirical ITCZ injection for Japanese patients, but also indicated a utility of the drug on future "presumptive" approach...
  36. ncbi Hypermethylation of gene promoters in hematological neoplasia
    C S Chim
    University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
    Hematol Oncol 20:167-76. 2002
    ..Emerging evidence suggests a possible prognostic value of gene promoter hypermethylation. Moreover, gene hypermethylation may also serve as a target for therapeutic invention by hypomethylating agents...
  37. ncbi Respiratory virus infections in adults with hematologic malignancies: a prospective study
    Rodrigo Martino
    Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
    Clin Infect Dis 36:1-8. 2003
    ..For both epidemiological and therapeutic considerations, frequent screening for respiratory viruses should be incorporated into the routine diagnostic study of patients with hematologic malignancies...
  38. pmc Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection
    Angela J Peck
    Department of Pediatrics, Children s Hospital and Regional Medical Center and University of Washington, Seattle, WA, USA
    Blood 110:1681-8. 2007
    ..004). Subclinical infection with PIV may help explain why infection-control programs that emphasize symptoms are effective against RSV and influenza but often not against PIV...
  39. pmc EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
    J J M van Dongen
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam Erasmus MC, Rotterdam, The Netherlands
    Leukemia 26:1908-75. 2012
    ....
  40. pmc Is exposure to formaldehyde in air causally associated with leukemia?--A hypothesis-based weight-of-evidence analysis
    Lorenz R Rhomberg
    Gradient, Cambridge, Massachusetts 02138, USA
    Crit Rev Toxicol 41:555-621. 2011
    ..Instead, apparent association between formaldehyde inhalation and leukemia in some human studies is better interpreted as due to chance or confounding...
  41. ncbi Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
    Chor Sang Chim
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    J Cell Mol Med 15:2760-7. 2011
    ..In NHL, hsa-miR-203 methylation was associated with concomitant methylation of other tumour suppressor miRNAs. The frequent hsa-miR-203 methylation in lymphoid malignancies suggested a pathogenetic role of hsa-miR-203 methylation...
  42. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  43. pmc Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
    Claudio G Brunstein
    University of Minnesota Medical Center, Minneapolis, MN, USA
    Blood 116:4693-9. 2010
    ..For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative...
  44. ncbi Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation
    J Maertens
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
    Blood 97:1604-10. 2001
    ..In conclusion, serial screening for GM, complemented by appropriate imaging techniques, is a sensitive and noninvasive tool for the early diagnosis of IA in high-risk adult hematology patients...
  45. ncbi Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit
    J Cadena
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Bone Marrow Transplant 40:151-5. 2007
    ..30-0.63 and OR: 0.38, 95% CI: 0.26-0.56). Cycling was associated with preserved antibiotic susceptibility among Gram-negatives, but with an increase in Enterococcus spp. and vancomycin and ampicillin resistance among enterococci...
  46. ncbi Comparison of PCR-ELISA and Real-Time PCR for invasive aspergillosis diagnosis in patients with hematological malignancies
    Ines Hadrich
    Fungal and Parasitic Molecular Biology Laboratory, Sfax School of Medicine, Sfax, Tunisia
    Med Mycol 49:489-94. 2011
    ..Combining real-time PCR and GMA detection for both serum and BAL samples enhances routine laboratory IA diagnosis...
  47. ncbi A prospective survey of febrile events in hematological malignancies
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Roma, Italy
    Ann Hematol 91:767-74. 2012
    ..The Hema e-Chart provided a complete system for the epidemiological study of infectious complications in HMs...
  48. ncbi 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia
    Brent L Wood
    Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cytometry B Clin Cytom 72:S14-22. 2007
    ..The 2006 Bethesda Consensus conference represents the first successful attempt to define a set of consensus reagents suitable for the initial evaluation of hematopoietic neoplasia...
  49. ncbi Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8 Taihaku cho, Hakata Ku, Fukuoka, Japan
    Int J Infect Dis 14:e171-5. 2010
    ..This study was performed to determine the local etiologic pattern of blood culture isolates and antibiotic resistance in febrile neutropenic patients with hematological malignancies...
  50. ncbi The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan
    Yi Ju Chen
    Taichung Veterans General Hospital, Taichung and National Yang Ming University, Taipei, Taiwan
    Arthritis Rheum 63:352-8. 2011
    ..The aim of this study was to investigate the relative risk of cancer in Taiwanese patients with RA and to identify groups of patients with a high risk of cancer...
  51. ncbi Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries
    Michael Hauptmann
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:1615-23. 2003
    ..We extended follow-up of a cohort of industrial workers to evaluate the association between formaldehyde exposure and lymphohematopoietic cancers...
  52. ncbi Pharmacological activation of the p53 pathway in haematological malignancies
    Manujendra N Saha
    Division of Cellular and Molecular Biology, Toronto General Hospital Research Institute, University of Toronto, Canada
    J Clin Pathol 63:204-9. 2010
    ..This review will highlight recent findings in the research into molecules capable of modulating p53 protein activities and mechanisms that activate the p53 pathway, restoring response to therapy in haematological malignancies...
  53. ncbi 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications
    B H Davis
    Trillium Diagnostics, Brewer, Maine, USA
    Cytometry B Clin Cytom 72:S5-13. 2007
    ..This report summarizes the appropriate use of diagnostic flow cytometry as determined by unanimous approval of these experienced practitioners...
  54. pmc Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009
    Marie Christine Nicolle
    Service d Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, France
    Haematologica 96:1685-91. 2011
    ..The study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis...
  55. ncbi Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia
    C Y Chen
    Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Epidemiol Infect 138:1044-51. 2010
    ..calcoaceticus-baumannii complex and vancomycin-resistant enterococci were also found during the study period. Emerging antimicrobial resistant pathogens are an increasing threat to neutropenic cancer patients...
  56. ncbi Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006
    C Bosetti
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Ann Oncol 19:29-43. 2008
    ..Occupational exposure to formaldehyde has been associated with excess risk of nasopharyngeal and selected other cancers...
  57. ncbi The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy
    Ray Hachem
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2493-9. 2008
    ..The objective of the current retrospective study was to compare the epidemiology of candidemia and its risk factors in patients who had hematologic malignancies(HM) with those in patients who had solid tumors (ST)...
  58. pmc Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
    Priya Koppikar
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 115:2919-27. 2010
    ..However, we did not observe a decrease in the size of the malignant clone in the bone marrow of treated mice at the end of therapy, which suggests that JAK2 inhibitor therapy, by itself, was not curative in this MPN model...
  59. ncbi Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia
    Leontine J R Van Elden
    Eijkman Winkler Institute of Medical Microbiology, Infectious Diseases and Inflammation, Department of Virology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Clin Infect Dis 34:177-83. 2002
    ....
  60. ncbi The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting
    P Lewis White
    Department of Medical Microbiology, National Public Health Service, Cardiff, United Kingdom
    Clin Infect Dis 42:479-86. 2006
    ..Invasive aspergillosis (IA) is associated with high mortality. Successful outcome with treatment is linked to early diagnosis. The utility of classic diagnostic methods, however, is limited...
  61. ncbi Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy
    Karen K Ballen
    Cancer Center and Department of Medicine, University of Massachusetts Memorial Health Care, Worcester, MA, USA
    Blood 100:442-50. 2002
    ..Low-dose TBI and allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy...
  62. ncbi The fundamental role of epigenetics in hematopoietic malignancies
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Blood Rev 20:1-13. 2006
    ..The ongoing exploration of basic events involved in altered gene transcription patterns and continued clinical investigative studies are helping to develop novel strategies for the diagnosis, prevention, and treatment of human cancer...
  63. ncbi Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  64. pmc Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
    Smita Bhatia
    City of Hope Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010 3000, USA
    Blood 105:4215-22. 2005
    ..4) when compared with siblings. Although mortality rates approach that of the general population after 10 years in certain subgroups, long-term survivors of autologous HCT continue to face challenges affecting their health and well-being...
  65. ncbi Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy
    Ulrich Schuler
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Dresden, Germany
    Onkologie 30:185-91. 2007
    ..Safety, tolerability and efficacy of itraconazole and amphotericin B (AMB) were compared for empirical antifungal treatment of febrile neutropenic cancer patients...
  66. pmc Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever
    Sun Hee Park
    Department of Internal Medicine, The Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea
    Korean J Intern Med 21:165-72. 2006
    ..The antifungal triazoles offer a potentially safer and effective treatment alternative to Amphotericin B dexoycholate...
  67. ncbi JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies
    William Vainchenker
    Institut Gustave Roussy PR 1, 94805 Villejuif, France
    Semin Cell Dev Biol 19:385-93. 2008
    ..In contrast, loss-of-function mutations of JAK3 and TYK2 lead to immunodeficiency. The role of JAKs as therapeutic targets is starting to expand, as more insights into their structure and activation mechanisms become available...
  68. ncbi A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
    B Bolwell
    Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 34:621-5. 2004
    ....
  69. ncbi New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
    Federica Toffalini
    Universite Catholique de Louvain, de Duve Institute, Brussels, Belgium
    Blood 116:2429-37. 2010
    ..Several mutations inactivating CBL, a key RTK E3 ubiquitin ligase, have been recently described. In this review, we discuss the possible links among RTK trafficking, signaling, and degradation in leukemic cells...
  70. pmc An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment
    Lamis K Eldjerou
    Allogeneic Bone Marrow Transplantation, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:3999-4006. 2010
    ..Thus, unit dominance is an in vivo phenomenon probably associated with a graft-versus-graft immune interaction mediated by CD34(-) cells...
  71. ncbi Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant
    N M A Blijlevens
    Department of Haematology, University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Bone Marrow Transplant 35:707-11. 2005
    ..These results confirm that the integrity and absorptive capacity of the gut is affected adversely by myeloablative regimens in general, although only two patterns of mucosal injury emerged depending on whether or not idarubicin was used...
  72. ncbi Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen
    P Frere
    Department of Medicine, Division of Haematology, University of Liege, Liege, Belgium
    Bone Marrow Transplant 37:411-8. 2006
    ..In conclusion, after NMSCT, infections are not frequent in the first 30 days post transplant but careful long-term monitoring is necessary thereafter...
  73. pmc Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database
    Peter A Hampshire
    Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK
    Crit Care 13:R137. 2009
    ....
  74. ncbi Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program
    Sergio Giralt
    The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis, USA
    Biol Blood Marrow Transplant 13:844-52. 2007
    ..However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials...
  75. ncbi Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program
    Chatchada Karanes
    City of Hope National Medical Center, Duarte, California, USA
    Biol Blood Marrow Transplant 14:8-15. 2008
    ..Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years...
  76. ncbi Invasive fungal infections in hematology: new trends
    R Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Av Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Ann Hematol 81:233-43. 2002
    ..However, the exact place of these agents in treating different IFI will need to be found in the near future...
  77. ncbi Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
    Georgios Chamilos
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Infect Dis 47:503-9. 2008
    ..Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis...
  78. ncbi Formaldehyde and lymphohematopoietic cancers: a review of two recent studies
    Philip Cole
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
    Regul Toxicol Pharmacol 58:161-6. 2010
    ..Both studies included subjects with considerable exposure to formaldehyde and both are focused on the myeloid leukemias...
  79. ncbi CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies
    J E C Bromberg
    Department of Neuro Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Neurology 68:1674-9. 2007
    ....
  80. ncbi Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies
    Enrico M Trecarichi
    Institute of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Infect 58:299-307. 2009
    ..Particular attention was focused on defining the impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance by the bacterial isolates on mortality...
  81. pmc The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
    Alexandra Smith
    Department of Health Sciences, University of York, UK
    Br J Haematol 148:739-53. 2010
    ..With respect to aetiology, several descriptive factors are highlighted and discussed, including the unexplained male predominance evident for most subtypes across all ages...
  82. pmc Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study
    M E Kroll
    Cancer Epidemiology Unit, Nuffield Department of Medicine, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK
    Br J Cancer 107:879-87. 2012
    ..The prospective Million Women Study provides sufficient power for reliable estimates of subtype-specific associations in women...
  83. ncbi Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee
    M A Slavin
    Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Intern Med J 41:102-9. 2011
    ..The group also provides recommendations for monitoring and surveillance of emerging resistance in those centres that have adopted FQ prophylaxis...
  84. pmc Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin
    Craig Sauter
    Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 17:1460-71. 2011
    ....
  85. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  86. ncbi Early infections in adult patients undergoing unrelated donor cord blood transplantation
    S Saavedra
    Bone Marrow Transplant Unit, Department of Haematology, Hospital Universitario La Fe, Valencia, Spain
    Bone Marrow Transplant 30:937-43. 2002
    ..and the low incidence of and lack of mortality due to CMV disease. This report confirms that infection is a major complication in adults undergoing UD-CBT...
  87. pmc Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms
    Agnes Fütterer
    Department of Immunology and Oncology, Centro Nacional de Biotecnología Consejo Superior de Investigaciones Científicas, Madrid, Spain
    J Clin Invest 115:2351-62. 2005
    ....
  88. ncbi [Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)]
    Emmanuel Guardiola
    CHU Jean Minjoz, Service Oncologie Medicale, 3, Bd Fleming, 25030 Besancon Cedex
    Bull Cancer 94:907-14. 2007
    ....
  89. ncbi Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 51:1705-10. 2010
    ..5 months (range, 12.6-48.5). Overall survival at 2 years was 59% (95% CI, 43-83%). These data suggest that patients with adequately controlled IA can tolerate RIC allo-SCT without significant post-transplant complications...
  90. ncbi Prospective study establishing a management plan for impacted third molar in patients undergoing hematopoietic stem cell transplantation
    Kenji Yamagata
    Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:146-52. 2011
    ..Although dental treatment before hematopoietic stem cell transplantation (HSCT) is essential to prevent serious infections from oral sources, the best management plan for impacted third molar (ITM) is unclear...
  91. ncbi Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases
    S Cesaro
    Pediatric Hematology Oncology, Department of Pediatrics, University of Padua, Padova, Italy
    Mycoses 51:497-504. 2008
    ..The high NPV makes LightCycler PCR a promising tool in addition to GM testing to design a strategy of pre-emptive antifungal therapy, although further validation studies are needed...
  92. pmc Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics
    Lina Shao
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77021 2039, USA
    J Mol Diagn 12:670-9. 2010
    ..This pilot study clearly demonstrates high sensitivity of oligonucleotide aCGH for potential use in diagnosis and follow-up in patients with hematological neoplasms...
  93. ncbi Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
    Coralia N Mihu
    Department of Infectious Diseases, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:5290-6. 2010
    ..Furthermore, clinical studies suggested that this combination may improve response of invasive aspergillosis (IA)...
  94. ncbi The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
    Livio Pagano
    Istituto di Ematologi, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Rome, Italy
    Haematologica 91:1068-75. 2006
    ..The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies...
  95. ncbi 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, NCI, NIH, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 72:S3. 2007
  96. ncbi Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning
    J S Kalpoe
    Department of Medical Microbiology, Leiden University Medical Center, Albinudreef 2, 2300 RC Leiden, The Netherlands
    Bone Marrow Transplant 40:137-43. 2007
    ..RIC with fludarabine, ATG and busulphan demonstrated safety comparable to conventional MAC with regard to frequency and severity of CMV infections within 100 days following T cell-depleted allo-SCT...
  97. ncbi Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults
    Willem J van Heeckeren
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    Br J Haematol 139:464-74. 2007
    ....
  98. ncbi Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients
    C Viscoli
    University of Genova and the National Institute for Cancer Research, Genoa, Italy
    Clin Microbiol Infect 12:212-6. 2006
    ..It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia...
  99. ncbi Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival
    P Ramirez
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 46:981-6. 2011
    ..DPR is a significant independent risk factor for increased TRM and poorer OS along with HLA-mismatched URD, but not UCB, grade II-IV acute GVHD, old age and advanced disease stage...
  100. ncbi Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients
    Olaf Penack
    Department of Hematology, Oncology, and Transfusion Medicine, Charite Campus Benjamin Franklin, Berlin, Germany
    Onkologie 30:621-6. 2007
    ..2 vs. 4.6%, p < 0.001) in high-risk patients with hematological malignancies and prolonged neutropenia...
  101. ncbi Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    Robin de Vries
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:75-90. 2008
    ..As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used...

Research Grants75

  1. FASEB SRC on Lysophospholipd Mediators in Health and Disease
    Julie D Saba; Fiscal Year: 2011
    ....
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  3. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  4. Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2010
    ..Its relatively small scale and concentrated focus promotes interaction and collaboration between participants across the globe. The meeting provides an excellent training environment for junior investigators and trainees. ..
  5. 24th Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2012
    ..Acquired abnormalities of FA genes and FA gene expression have been reported in patients with sporadic malignancies of plasma cells, leukemia, head and neck cancer, lung cancer, and ovarian cancer. ..
  6. Targeting CC-Chemokine Receptor 7 for the prevention of graft-versus-host disease
    JAMES M COGHILL; Fiscal Year: 2013
    ..Through these experiences, Dr. Coghill will obtain the skills necessary to transition to an independent, NIH funded laboratory investigator. ..
  7. Cell signaling as a leukemia biomarker
    JAMES WILLIAM JACOBBERGER; Fiscal Year: 2013
    ....
  8. Pluripotent stem cell-derived HSCs: improvements and molecular mechanisms
    Patrick Cahan; Fiscal Year: 2013
    ..An extensive program of formal training, course-work, meetings with the advisory committee, and dedicated supervision and mentorship by Dr. Daley will ensure that these goals are achieved. ..
  9. PRE- AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
    J Evan Sadler; Fiscal Year: 2013
    ..Completion of this program will prepare talented trainees for careers in basic and translational hematology research, to make discoveries that will transform the diagnosis and treatment of hematologic diseases. ..
  10. Modulation of host immune defense by Pneumocystis beta-glucans
    EVA MARIA CARMONA PORQUERA; Fiscal Year: 2013
    ....
  11. Parental age at birth and risk of adult-onset cancer in female offspring
    Yani Lu; Fiscal Year: 2013
    ..The long-term goal of the research is to explore biomarkers that link parental age and cancer risk to clarify etiology, and thus provide potential targets for prevention. ..
  12. Validation of microRNAs as therapeutic targets in hematological malignancies
    Natarajan Muthusamy; Fiscal Year: 2013
    ..Therefore, we propose here to replace the low levels of natural microRNAs in leukemia cells with synthetic microRNAs as novel therapeutic approach to leukemia patients. ..
  13. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    ..We therefore anticipate rapid translation of the optimized promising pretargeted RIT into our clinical RIT HCT program for AML and MDS. ..
  14. CD4+ T cells in Invasive Aspergillosis
    Amariliz Rivera; Fiscal Year: 2012
    ..Moreover, the successful completion of the proposed studies is likely to contribute to the development of novel therapeutic interventions to combat invasive fungal diseases. ..
  15. Novel therapies for Fanconi anemia
    DAVID A contact WILLIAMS; Fiscal Year: 2010
    ....
  16. Autoimmunity Center of Excellence - Rochester
    R John Looney; Fiscal Year: 2013
    ..Therefore, we propose inhibiting CXCL13 using a human monoclonal antibody. The primary clinical outcome will again be adverse events. The primary mechanistic outcome will be changes in peripheral blood memory B cells. ..
  17. Twenty-first Annual Fanconi Anemia Research Fund Scientific Symposium
    Grover Bagby; Fiscal Year: 2009
    ..Acquired abnormalities of FA genes and FA gene expression have been reported in patients with sporadic malignancies of plasma cells, leukemia, head and neck cancer, lung cancer, and ovarian cancer. ..
  18. The Role of hPso4 in DNA Repair and Chemotherapy Resistance
    Montaser Shaheen; Fiscal Year: 2013
    ..We will deplete this E2 and evaluate if this will achieve the same chemosensitivity as depleting hPso4. This will open the opportunity to identify Ubc3 small molecule inhibitors as cancer therapy. ..
  19. FASEB SRC on Hematopoietic Malignancies
    MICHELLE ALICE KELLIHER; Fiscal Year: 2011
    ..The meeting also fosters new collaborations and the training of graduate students, post---doctoral fellows and early stage investigators in this important research field. ..
  20. Role of Cited2 in Hematopoiesis
    Yu Chung Yang; Fiscal Year: 2011
    ....
  21. There Will Be Blood: Stem Cell Niche Driven Derivation of HSC from ES Cells
    PAUL JOHN SIMMONS; Fiscal Year: 2010
    ..This proposal seeks to develop markedly improved strategies to derive HSC from pluripotent stem cells as a means to overcome this limitation and to further the development of novel cellular therapies for treating blood diseases. ..
  22. Role of POZ-zinc finger proteins in tumorigenesis.
    Pier Paolo Pandolfi; Fiscal Year: 2013
    ..In view of the critical role exerted by this protein in tumorigenesis and embryonic development the further elucidation of POKEMON/LRF function and role in human cancer is of great relevance to biomedical research. ..
  23. Histone Deacetylase Inhibition: A Novel Approach to Cardioprotection
    Ting C Zhao; Fiscal Year: 2012
    ....
  24. Suppression of genomic instability by tuning the DNA damage response at telomeres
    RACHEL L FLYNN; Fiscal Year: 2012
    ....
  25. System for Rapid Generation of Aptamers for Transplant Therapies
    KAREN QIAN; Fiscal Year: 2010
    ....
  26. Suppression of genomic instability by tuning the DNA damage response at telomeres
    RACHEL L FLYNN; Fiscal Year: 2013
    ..Receipt of this award would not only allow me to expand my research plan, but also establish myself as a primary investigator in the field of cancer biology. ..
  27. Novel mechanisms of immune activation following allogeneic, hematopoietic stem ce
    JOHN JAMES LETTERIO; Fiscal Year: 2013
    ....
  28. Role of a pro-apoptotic Bcl-2 protein in the survival and death of leukemia cells
    Ameeta Kelekar; Fiscal Year: 2013
    ....
  29. Genetics of risk of chemotherapy-induced cardiotoxicity in cancer survivors
    Peter Demant; Fiscal Year: 2013
    ..This will have strong prospects to uncover novel pathways influencing ACT and open the way for definition of individual ACT pathogenesis in mice and humans. ..
  30. Genome Wide Admixture Scan for Multiple Myeloma in African Americans
    CHRISTOPHER ALAN HAIMAN; Fiscal Year: 2013
    ..Our ultimate goal is to reduce the health disparity experienced by African Americans due to this fatal cancer. ..
  31. The Molecular Mechanisms by which the Paf Oncogene Mediates Hematopoiesis
    Lisa K Denzin; Fiscal Year: 2013
    ..The data from these experiments represent an essential step towards delineating the molecular mechanisms by which Paf functions to mediate hematopoiesis. ..
  32. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2013
    ..abstract_text> ..
  33. Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery
    ALISON ANNE MCCORMICK; Fiscal Year: 2010
    ..Unlike current therapies, custom vaccines are easily made, and may facilitate widespread adoption of individualized patient immunotherapy. ..
  34. In Vivo Imaging of bcl-2 Expression in Lymphoma
    Michael R Lewis; Fiscal Year: 2012
    ..5% of its victims are U.S. war veterans. The goal of the proposed research is central to the VHA mission of providing primary and specialized care to cancer patients who are veterans. ..
  35. Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD
    Leslie S Kean; Fiscal Year: 2013
    ....
  36. RESEARCH TRAINING IN HEMATOLOGY
    JOHN PATRICK SHEEHAN; Fiscal Year: 2012
    ..abstract_text> ..
  37. Regulation and function of nuclear envelope proteins in myelopoiesis and leukemia
    PETER CHARLES WIGRAM GAINES; Fiscal Year: 2010
    ....
  38. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo R Luo; Fiscal Year: 2012
    ..Lastly, PtdIns(3,4,5)P3 signaling can also be augmented by disrupting InsP3KB;and thus we will explore whether disruption of InsP3KB can also reduce the severity of neutropenia-related pneumonia (Aim IV). ..
  39. EMBRYONIC STEM CELLS INDUCE SPECIFIC GRAFT TOLERANCE
    Nicholas Zavazava; Fiscal Year: 2012
    ..Achievement of these goals will establish ESC as a new source of hematopoietic cells that can be used for tolerance induction without harsh immunosuppression of the recipient. ..
  40. Delta-like ligand 4+ dendritic cells and induction of alloimmunity
    Yi Zhang; Fiscal Year: 2013
    ....
  41. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2013
    ..In this proposal, we plan to determine how APC plays a role in the pathogenesis of MDS and t-MDS/t-AML, ultimately leading to new effective therapeutic strategies for these diseases. ..
  42. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
    Hing C Wong; Fiscal Year: 2012
    ..Positive outcomes from this proposed study would provide justification for clinical development of this complex as a safe, durable, potent and cell-mediated immunotherapy to treat patients with multiple myeloma. ..
  43. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    Golam Mohi; Fiscal Year: 2013
    ..The results of these studies may identify new therapeutic targets for MPDs. Moreover, our inducible JAK2V617F knock-in mouse will provide a unique and reproducible animal model to test novel therapies for JAK2V617F-associated MPDs. ..
  44. The role of complement system in alloimmune responses
    Qing Ma; Fiscal Year: 2013
    ....
  45. Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2
    Zhong Yin Zhang; Fiscal Year: 2013
    ..In addition, potent and selective SHP2 inhibitors will also serve as powerful research tools to delineate the function of SHP2 in normal physiology and to elucidate the events underlying SHP2-evoked transformation. ..
  46. Function of MTG16/ETO2 in acute leukemia
    SCOTT HIEBERT; Fiscal Year: 2010
    ..Therefore, we will define the action of Mtg16 in the hematopoietic stem cell and determine the function of this key regulatory gene family in stem cell biology and cancer. ..
  47. Validating Syk as a Target for AML Therapy
    Kimberly Stegmaier; Fiscal Year: 2013
    ..These studies, within the five year time frame of this grant, will have immediate translational relevance and inform the development of a clinical trial testing Syk inhibition in patients with relapsed/refractory AML. ..
  48. Inhibition of Histone Deacetylase in Myeloproliferative Neoplasms
    Golam Mohi; Fiscal Year: 2012
    ..The data generated from these studies will lay the groundwork for Phase I and II clinical trials of vorinostat in MPNs. ..
  49. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2013
    ..End of Abstract) ..
  50. NK and T Cell Regulation of ES-Derived Hematopoietic Progenitor Cell Engraftment
    WILLIAM TABAYOYONG; Fiscal Year: 2010
    ..When completed, these studies will provide a characterization of the immune response directed against transplanted ES-derived HPC and may provide further insight into the immunobiology of other ES-derived cellular therapies. ..
  51. 23rd Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2011
    ..This application seeks partial support for this meeting, scheduled to be held in Barcelona, Spain in October 2011. ..
  52. TGF beta-induced apoptosis in B-lymphocytes
    Philip H Howe; Fiscal Year: 2013
    ..Our research may identify factors and important regulatory pathways that could be used therapeutically to modulate Bim expression in vivo. ..
  53. ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE
    Mark Lim; Fiscal Year: 2010
    ..We will also maintain a close contact during Phase II with two leading diagnostic companies, LabCorp and Genzyme Genetics, who have expressed an interest in the ultimate commercialization of the DRAMA-ACD approach. ..
  54. Phase 1 of AR-42 in relapsed CLL, lymphoma, myeloma
    Craig C Hofmeister; Fiscal Year: 2012
    ....
  55. Identification and Significance of Biologic Mediators in Red Cell Concentrates
    Richard P Phipps; Fiscal Year: 2012
    ..Our research will discover explanations for these effects, and we will devise inexpensive strategies to reduce these complications ..
  56. The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation
    Jiwang Zhang; Fiscal Year: 2013
    ..The predicted outcome will greatly help our ability to expand hematopoietic stem cells in vitro and hence improve the outcome of clinical stem cell transplantation. ..
  57. A Topical Host Defense Peptide Mimetic for Oral Mucositis
    Richard W Scott; Fiscal Year: 2012
    ..Standard management options for mucositis are essentially palliative. We propose to develop a novel topical anti-mucositis therapeutic to ameliorate this pernicious side effect of cancer therapy. ..
  58. Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma
    Jonathan Licht; Fiscal Year: 2013
    ..These data lead to our overarching hypothesis that aberrant overexpression of MMSET leads to deregulated gene expression in B cells, contributing to the pathogenesis of myeloma. ..
  59. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald W Kufe; Fiscal Year: 2012
    ..The proposed work will expand our understanding of how agents that disrupt redox balance induce terminal differentiation in the laboratory and in patients on clinical trials. ..
  60. Gfi-proteins in hematopoietic development
    Stuart H Orkin; Fiscal Year: 2013
    ..One long-term outcome of the findings of this work may be improved methods for expansion of blood stem cells, an advance that would facilitate many treatments based on bone marrow transplantation. ..
  61. The Role of the Stem Cell Niche in ALL
    Laura F Gibson; Fiscal Year: 2013
    ..Understanding the mechanisms by which the Ph+ leukemic stem cell is protected by the bone marrow microenvironment will increase our ability to design novel treatment strategies that are more effective in targeting this population. ..
  62. Dot 1 Complex, Transcriptional Elongation Control and Human Cancer
    Ali Shilatifard; Fiscal Year: 2013
    ....
  63. Substrata Interactions of Normal and Leukemic Hematopoietic Stem Cells
    Jane Liesveld; Fiscal Year: 2009
    ..They also have implication for understanding of survival and proliferation of normal stem cells which would have impact on stem cell transplantation and implantation therapies. ..
  64. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  65. IMMUNOREGULATORY EFFECTS OF THE INTERFERONS
    Howard Ozer; Fiscal Year: 1992
    ..They have demonstrated significant clinical activity in hematologic neoplasms and our own data imply a direct, antiproliferative mechanism of action mediated via specific cell surface ..
  66. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2007
    ..abstract_text> ..
  67. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2003
    ....
  68. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  69. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ....
  70. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..We will test all these hypotheses by collecting individual-patient data on each outcomes of interest from the existing data sets (i.e. from published and unpublished randomized studies) using the techniques of SR/MA. ..
  71. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2005
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  72. Genetic Variation in Vitamin D Metabolism and BMT Outcomes
    KIMBERLY ROBIEN; Fiscal Year: 2009
    ....
  73. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2006
    ..abstract_text> ..
  74. DLI using genetically modified T cells: Phase 1 trial
    John Dipersio; Fiscal Year: 2005
    ..abstract_text> ..
  75. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ....